UK Companies House feature
IOVANCE BIOTHERAPEUTICS UK LTD
Profile
- Company number
- 14607528
- Status
- Active
- Incorporation
- 2023-01-20
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 21100
- Hubs
- UK Healthcare
Accounts
Pending extraction
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of twelve months from when the financial statements are authorised for issue.”
Subsidiaries
- Iovance Biotherapeutics UK SP Ltd · 100% held · United Kingdom · Manufacturing
Significant events
- “In March 2024, the Food and Drug Administration (FDA) granted regulatory approval for the development of Amtagvi®. This triggered a milestone payment of £41,670,000 as a consequence of the approval.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
2 active · 1 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ROCHE, Corleen Marie | Director | 2025-08-06 | Oct 1965 | American |
| VOGT, Frederick | Director | 2023-01-20 | Aug 1973 | American |
Show 1 resigned officer
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BELLEMIN, Jean-Marc | Director | 2023-01-20 | 2025-06-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Iovance Biotherapeutics, Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2023-01-20 | Active |
Filing timeline
Last 12 of 12 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-02-11 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2025-10-21 | AA | accounts | accounts with accounts type full |
| 2025-09-08 | AP01 | officers | appoint person director company with name date |
| 2025-09-05 | TM01 | officers | termination director company with name termination date |
| 2025-03-18 | AA | accounts | accounts with accounts type full |
| 2025-02-06 | PSC05 | persons-with-significant-control | change to a person with significant control |
| 2025-01-31 | CS01 | confirmation-statement | confirmation statement with updates |
| 2024-11-15 | AA01 | accounts | change account reference date company previous shortened |
| 2024-11-15 | SH01 | capital | capital allotment shares |
| 2024-01-26 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2023-06-12 | AD01 | address | change registered office address company with date old address new address |
| 2023-01-20 | NEWINC | incorporation | incorporation company |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Activity Score
Composite activity score · components 0–100 · reference 2026-05-10
38.3
COLD
/ 100
- Filings velocity 33
- Capital events 20
- Officer churn 50
- Headcount trajectory 50
- Accounts trajectory 50
- 4 filing(s) in last 12 months
- 1 capital event(s) in last 24 months
- 1 appointed, 1 resigned (12mo)